SV2002000527A - Uso de cepas de parapoxvirus ovis contra fibrosis de organos ref. lea 34714-sv - Google Patents

Uso de cepas de parapoxvirus ovis contra fibrosis de organos ref. lea 34714-sv

Info

Publication number
SV2002000527A
SV2002000527A SV2001000527A SV2001000527A SV2002000527A SV 2002000527 A SV2002000527 A SV 2002000527A SV 2001000527 A SV2001000527 A SV 2001000527A SV 2001000527 A SV2001000527 A SV 2001000527A SV 2002000527 A SV2002000527 A SV 2002000527A
Authority
SV
El Salvador
Prior art keywords
vapes
ref
read
organ fibrosis
parapoxvirus ovis
Prior art date
Application number
SV2001000527A
Other languages
English (en)
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV2002000527A publication Critical patent/SV2002000527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24261—Methods of inactivation or attenuation
    • C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO EN HUMANOS DE PARAPOXVIRUS INACTIVADOS EN LA PROFILAXIS Y TRATAMIENTO DE ENFEREMEDADES QUE ESTAN ACOMPAÑADAS POR UN AUMENTO DE LA CONCRECION DE COLAGENOS, PUDIENDO CORCERNIR TANTO A ORGANOS INTERNOS, COMO POR EJEMPLO EL HIGADO, COMO TAMBIEN A LA PIEL Y SUS ANEXOS. SE REFIERE ESPECIALMENTE A FIBROSIS HEPATICA O CIRROSIS HEPATICA COMO CONSECUENCIA DE HEPATITIS VIRAL O ENFERMEDADES HEPATICAS INDUCIDAS POR EL ETANOL, ASI COMO FIBROSIS QUISTICA
SV2001000527A 2000-07-11 2001-07-11 Uso de cepas de parapoxvirus ovis contra fibrosis de organos ref. lea 34714-sv SV2002000527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen

Publications (1)

Publication Number Publication Date
SV2002000527A true SV2002000527A (es) 2002-10-24

Family

ID=7648485

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000527A SV2002000527A (es) 2000-07-11 2001-07-11 Uso de cepas de parapoxvirus ovis contra fibrosis de organos ref. lea 34714-sv

Country Status (14)

Country Link
JP (2) JP5587950B2 (es)
KR (1) KR100845643B1 (es)
CN (1) CN101444539B (es)
AT (1) ATE445413T1 (es)
BR (1) BRPI0112411B8 (es)
DE (2) DE10122233A1 (es)
DK (1) DK1303302T3 (es)
DO (1) DOP2001000210A (es)
EC (1) ECSP034420A (es)
ES (1) ES2332355T3 (es)
PE (1) PE20020218A1 (es)
PT (1) PT1303302E (es)
SV (1) SV2002000527A (es)
ZA (1) ZA200300276B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK0885013T3 (da) * 1996-04-15 2001-11-05 Anton Prof Dr Med Vet Dr Mayr Anvendelse af multipotente paramunitetsinducere fra svækkede, ikke-immunogene poxvirus eller parapoxvirus til fremstilling af lægemidler

Also Published As

Publication number Publication date
JP2014196329A (ja) 2014-10-16
DE10122233A1 (de) 2002-01-24
BR0112411A (pt) 2003-05-27
ES2332355T3 (es) 2010-02-03
JP2012214492A (ja) 2012-11-08
JP5950964B2 (ja) 2016-07-13
KR20030019562A (ko) 2003-03-06
ZA200300276B (en) 2004-04-13
PT1303302E (pt) 2009-11-11
CN101444539A (zh) 2009-06-03
BRPI0112411B1 (pt) 2018-02-27
DOP2001000210A (es) 2002-12-15
ECSP034420A (es) 2003-03-10
PE20020218A1 (es) 2002-05-19
DE50115181D1 (de) 2009-11-26
CN101444539B (zh) 2016-07-06
JP5587950B2 (ja) 2014-09-10
DK1303302T3 (da) 2010-02-08
KR100845643B1 (ko) 2008-07-10
BRPI0112411B8 (pt) 2021-05-25
ATE445413T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
Wu et al. Evaluation of tyrosinase inhibitory, antioxidant, antimicrobial, and antiaging activities of Magnolia officinalis extracts after Aspergillus niger fermentation
EP0693281A3 (en) Pharmaceutical preparations containing fluoxetine
WO2003032941A3 (de) Kosmetische und/oder dermatologische wirkstoffkombination
DE60130135D1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
ATE284996T1 (de) Papiertuch enthaltend antivirale wirkstoffe die hautfreundlich sind
TR200200725T2 (tr) Anyonik amino asit bazlı yüzey aktif maddeler.
NO985980D0 (no) Lektinpreparater og anvendelser derav
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
ES2127613T3 (es) Utilizacion de un antagonista de tnf-alfa para el tratamiento de rojeces cutaneas de origen neurogeno.
PE20020218A1 (es) Uso de cepas de parapoxvirus ovis contra fibrosis de organos
AU2309102A (en) Dermatological formulations
Rimbau et al. Antiinflammatory activity of some extracts from plants used in the traditional medicine of North‐African countries
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
AU5487101A (en) Cosmetic or dermatological product comprising a freeze-dried hydrocolloid composition
NO20052960L (no) Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi
TR200200724T2 (tr) Cilde sürülebilen farmasötik bileşimlerin antimikrobik etkisinin arttırılması için yağlı asit/amino asit sabunlarının kullanımı
Dartsch The potential of Asparagus‐P® to inactivate reactive oxygen radicals
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
EP1038529A3 (en) Agent for increasing chemokine production
Fox Stop Trying Too Hard to Kill Bacteria
CA2508238A1 (en) Reovirus for the treatment of neoplasia
Baishya Topical ketoconazole therapy in a recalcitrant case of seborrhoeic dermatitis
Verheugt Differential dose effect of aspirin in the primary prevention of myocardial infarction
FR2779052B1 (fr) Compositions capillaires contenant un extrait de pfaffia paniculata

Legal Events

Date Code Title Description
FD Lapse